<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617459</url>
  </required_header>
  <id_info>
    <org_study_id>Zhaoke-201506-Levobetaxolol</org_study_id>
    <nct_id>NCT02617459</nct_id>
  </id_info>
  <brief_title>Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension</brief_title>
  <official_title>A Multicenter, Randomized, Open-label, Positive-controlled, Parallel-group Clinical Trial of Levobetaxolol Hydrochloride Eye Drops in Patients With Primary Open-angle Glaucoma or Ocular Hypertension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with glaucoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with primary
      open-angle glaucoma or ocular hypertension.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease of intraocular pressure at week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Decrease of intraocular pressure at week 8</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease of intraocular pressure at week 2</measure>
    <time_frame>2 weeks</time_frame>
    <description>Decrease of intraocular pressure at week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of intraocular pressure at week 4</measure>
    <time_frame>4 weeks</time_frame>
    <description>Decrease of intraocular pressure at week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of visual field deficiency at week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Decrease of visual field deficiency at week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease of nerve fiber layer thickness at week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>Decrease of nerve fiber layer thickness at week 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity test with Snellen chart at week 2</measure>
    <time_frame>2 weeks</time_frame>
    <description>visual acuity test with Snellen chart at week 2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity test with Snellen chart at week 4</measure>
    <time_frame>8 weeks</time_frame>
    <description>visual acuity test with Snellen chart at week 4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>visual acuity test with Snellen chart at week 8</measure>
    <time_frame>8 weeks</time_frame>
    <description>visual acuity test with Snellen chart at week 8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">366</enrollment>
  <condition>Primary Open-angle Glaucoma</condition>
  <condition>Ocular Hypertension</condition>
  <arm_group>
    <arm_group_label>Levobetaxolol eye drops</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levobetaxolol eye drops 5ml/25mg per bottle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Betaxolol eye drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Betaxolol eye drops 5ml/12.5mg per bottle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levobetaxolol eye drops</intervention_name>
    <description>one drop per time; twice daily</description>
    <arm_group_label>Levobetaxolol eye drops</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Betaxolol eye drops</intervention_name>
    <description>one drop per time; twice daily</description>
    <arm_group_label>Betaxolol eye drops</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Agreed to participate in this clinical trial and informed consent;

          -  Aged 18 to 70 years of age, male or female;

          -  In line with primary open-angle glaucoma diagnostic criteria, IOP ≥18mmHg;

          -  or in compliance with ocular hypertension diagnostic criteria, intraocular pressure&gt;
             21mmHg

        Exclusion Criteria:

          -  Known or suspected to be allergic to investigational drugs and materials

          -  has been diagnosed with angle-closure glaucoma, absolute glaucoma, glaucoma ciliary
             body syndrome, secondary glaucoma.

          -  merge various retinal lesions, such as retinal detachment, retinal vein occlusion,
             retinitis pigmentosa.

          -  merge associated with eye infections or cornea, iris, lens obvious lesions, or
             one-eyed patients.

          -  During the trial who must wear contact lenses, or nearly three months experts any eye
             surgery or laser treatment.

          -  Need systemic β-blocker therapy during the study.

          -  with severe kidney disease, or abnormal liver function tests (ALT, AST≥ 1.5 times the
             upper limit of normal, SCr&gt; upper limit of normal).

          -  merge sinus bradycardia, over Ⅰ degree atrioventricular block, cardiogenic shock,
             heart failure, symptomatic hypotension or other serious heart, lung diseases (such as
             bronchial asthma or a history of bronchial asthma, chronic obstructive lung disease,
             bronchospasm, respiratory failure, etc.).

          -  merge hyperthyroidism, myasthenia gravis, diabetes, advanced cancer, blood and
             hematopoietic system diseases, or other serious or progressive disease systems.

          -  associated with neurological and psychiatric disorders

          -  suspect or indeed alcohol, drug abuse history.

          -  pregnancy, lactation or recent fertility planner.

          -  The researchers believe other circumstances were not involved in this trial.

          -  participate in other clinical trials within three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Ge, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Ophthalmic Center, Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Ge, MD</last_name>
    <phone>+86-20-87330000</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan ophthalmic center, Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Ge, MD</last_name>
      <phone>0+86-20-87330000</phone>
    </contact>
    <investigator>
      <last_name>Jian Ge, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>November 18, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Safety</keyword>
  <keyword>efficacy</keyword>
  <keyword>Levobetaxolol eye drops</keyword>
  <keyword>Chinese patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
    <mesh_term>Ocular Hypertension</mesh_term>
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Betaxolol</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

